Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients.

More about this publication

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • Volume 17
  • Issue nr. 7
  • Pages A640
  • Publication date 01-11-2014

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.